April 8, 2025

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

April 7, 2025

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

March 27, 2025

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

February 18, 2025

CureVac Earns Repeat Recognition by LexisNexis® as One of the World’s Top Innovators

November 12, 2024

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

November 7, 2024

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

November 4, 2024

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

November 4, 2024

CureVac to Present at the 12th International mRNA Health Conference

October 28, 2024

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

September 13, 2024

CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

September 12, 2024

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

September 9, 2024

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

August 15, 2024

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

August 15, 2024

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

August 15, 2024

CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

July 11, 2024

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

July 3, 2024

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

July 3, 2024

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

June 24, 2024

[English only] CureVac Announces Voting Results of General Meeting

May 28, 2024

CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

May 23, 2024

CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update

April 24, 2024

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

April 24, 2024

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

April 24, 2024

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

April 18, 2024

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

April 16, 2024

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

April 4, 2024

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

January 17, 2024

[Form 6-K only / English only] CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock

January 5, 2024

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

December 19, 2023

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

November 14, 2023

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

November 1, 2023

CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

October 31, 2023

CureVac to Report Third Quarter and First Nine Months 2023 Financial Results and Business Updates on November 14, 2023

September 28, 2023

CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany

September 12, 2023

CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage

August 17, 2023

CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update

August 1, 2023

CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK

July 14, 2023

CureVac Announces Update to the Management Team

July 13, 2023

CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights

June 20, 2023

CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

June 20, 2023

CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board

June 19, 2023

[English only] CureVac Announces Voting Results of General Meeting

May 30, 2023

CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update

May 19, 2023

CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech

May 8, 2023

CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

April 25, 2023

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update

April 18, 2023

CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023

March 28, 2023

[English only] CureVac Announces Voting Results of Extraordinary General Meeting

February 10, 2023

CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares

February 8, 2023

CureVac Announces Pricing of Upsized Public Offering of Common Shares

January 9, 2023

CureVac Appoints Alexander Zehnder as CEO From April 1, 2023

February 6, 2023

CureVac Announces Proposed Public Offering of Common Shares

February 1, 2023

CureVac Welcomes Myriam Mendila as New Chief Development Officer

January 6, 2023

CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

January 31, 2023

CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis®

December 14, 2022

CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program

January 30, 2023

CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs

November 16, 2022

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update

November 11, 2022

CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

November 10, 2022

CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022

August 18, 2022

CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update

August 18, 2022

CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

July 5, 2022

CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech

June 22, 2022

CureVac Announces Voting Results of General Meeting

June 8, 2022

CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform

June 8, 2022

CureVac Announces Changes of CDO – Myriam Mendila to succeed Klaus Edvardsen

May 25, 2022

CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update

May 25, 2022

CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development

April 28, 2022

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update

April 22, 2022

CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022

April 21, 2022

CureVac and GSK’s Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study

April 11, 2022

CureVac and GSK Enter into Pandemic Preparedness Contract with German Government

March 30, 2022

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

March 1, 2022

CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer®

February 10, 2022

CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK

January 17, 2022

CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry

November 18, 2021

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update

November 18, 2021

CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine

November 10, 2021

CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response

October 12, 2021

CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology

September 14, 2021

CureVac Streamlines European Network for mRNA Product Manufacturing

August 31, 2021

CureVac’s CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet

August 30, 2021

CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

August 16, 2021

CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update

August 16, 2021

Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

June 30, 2021

CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60

June 30, 2021

CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer®

June 24, 2021

CureVac Announces Voting Results of General Meeting

June 23, 2021

CureVac Provides Supervisory Board Update

June 16, 2021

CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV

June 2, 2021

CureVac Appoints Klaus Edvardsen as Chief Development Officer

May 28, 2021

CureVac’s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation

May 26, 2021

CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates

May 13, 2021

Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study

April 19, 2021

CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic

April 15, 2021

CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020

April 9, 2021

CureVac to Report Fourth Quarter and Full-Year 2020 Financial Results and Business Updates on April 15, 2021

March 30, 2021

Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac’s COVID-19 Vaccine Candidate, CVnCoV

March 23, 2021

CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study

March 22, 2021

CureVac Expands CVnCoV COVID-19 Vaccine Candidate Clinical Trial Analyses to Include Phase 2b/3 Variant Specification and Efficacy Secondary Endpoint to Phase 2a

March 4, 2021

CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV

February 18, 2021

CureVac to Participate in Upcoming Investor Conferences

February 12, 2021

CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV

February 5, 2021

CureVac to Host Conference Call on COVID-19 Partnership Update on February 5, 2021

February 5, 2021

CureVac and UK Government to collaborate on development of vaccines against SARS-CoV-2 variants

February 4, 2021

CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma

February 4, 2021

CureVac Announces Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

February 3, 2021

GSK and CureVac to develop next generation mRNA COVID-19 vaccines – joint press release

February 2, 2021

CureVac Announces Closing of $450 million Follow-on Public Offering of Common Shares

February 1, 2021

CureVac and Rentschler Biopharma ramp up Manufacturing of COVID-19 Vaccine, CVnCoV – joint press release

January 28, 2021

CureVac Announces Pricing of $450 million Follow-on Public Offering of Common Shares

January 25, 2021

CureVac Announces Proposed Public Offering of Common Shares

January 11, 2021

CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection

January 7, 2021

CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV – joint press release

December 21, 2020

CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare Workers

December 14, 2020

CureVac Commences Global Pivotal Phase 2b/3 Trial for COVID-19 Vaccine Candidate, CVnCoV

December 9, 2020

CureVac and Fareva Sign Agreement For Fill & Finish Manufacturing of Curevac’s COVID-19 Vaccine Candidate, CVnCoV – joint press release

December 8, 2020

[German only] Moderne Wärme im Cyber Valley: Stadtwerke Tübingen versorgen neues Produktionsgebäude von CureVac – gemeinsame Pressemitteilung

December 4, 2020

CureVac Appoints Antony Blanc as Chief Business Officer and Chief Commercial Officer

November 30, 2020

CureVac Announces Financial Results and Business Updates for the Third Quarter and First Nine Months of 2020

November 26, 2020

CureVac to Report Third Quarter and First Nine Months 2020 Financial Results and Business Updates on November 30, 2020

November 23, 2020

CureVac and WACKER Sign Manufacturing Contract for CureVac’s COVID-19 Vaccine Candidate, CVnCoV – joint press release

November 17, 2020

CureVac Establishes European-Based Network to Ramp Up Manufacturing of its COVID-19 Vaccine Candidate, CVnCoV

November 16, 2020

European Commission Announces That Tomorrow It Will Authorize the Agreement with CureVac for the Supply of up to 405 Million Doses of mRNA-Based COVID-19 Vaccine Candidate, CVnCoV

November 12, 2020

CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Suitable for Standard Fridge Temperature Logistics

November 10, 2020

CureVac Publishes Detailed Interim Phase 1 Data of its COVID-19 Vaccine Candidate, CVnCoV

November 2, 2020

CureVac Reports Positive Interim Phase 1 Data for its COVID-19 Vaccine Candidate, CVnCoV

October 23, 2020

CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV

September 29, 2020

CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate

September 4, 2020

CureVac Expected to Receive up to 252 million Euros from the German Federal Ministry of Research for Further COVID-19 Vaccine Development and Production Capacity Expansion

August 20, 2020

CureVac and European Commission in Advanced Discussions to Supply up to 405 million doses of potential mRNA-based COVID-19 Vaccine

August 18, 2020

CureVac Announces Closing of Initial Public Offering

August 14, 2020

CureVac Announces Pricing of Initial Public Offering

August 10, 2020

CureVac Announces Proposed Initial Public Offering of Common Shares

August 4, 2020

CureVac Appoints Dr. Franz-Werner Haas as Chief Executive Officer and Dr. Igor Splawski as Chief Scientific Officer

July 21, 2020

CureVac Raises a Total of USD 640 Million in Private Financing Round

July 20, 2020

GSK and CureVac announce strategic mRNA technology collaboration

July 6, 2020

Germany: EIB and European Commission provide CureVac with a €75 million financing for vaccine development and expansion of manufacturing

July 1, 2020

Please note: Currently, there is no possibility to purchase shares of CureVac AG. Offers to purchase shares in CureVac AG are fraudulent.

June 17, 2020

CureVac Receives Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate

June 15, 2020

German Federal Government invests 300 Million Euros in CureVac

May 14, 2020

CureVac’s Optimized mRNA Platform Provides Positive Pre-Clinical Results at Low Dose for Coronavirus Vaccine Candidate

April 2, 2020

Jean Stéphenne Elected as New Chairman of the Supervisory Board of CureVac

March 17, 2020

COVID-19: Conference Call on Current Developments

March 16, 2020

CureVac announces leadership update

March 15, 2020

CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide

March 11, 2020

Company Founder Ingmar Hoerr Succeeds Daniel Menichella as CEO of CureVac AG

March 3, 2020

CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. President Donald Trump and Members of Coronavirus Task Force

February 26, 2020

CureVac Appoints Alan Kimura, MD, PhD as Head of the Newly Created Department “Rare Diseases”

January 31, 2020

CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019

January 7, 2020

CureVac Announces Positive Results in Low Dose – 1 µg – Rabies Vaccine Clinical Phase 1 Study

December 19, 2019

Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics

December 2, 2019

CureVac Granted Manufacturing Authorization for its Third GMP Production Suite

November 20, 2019

CureVac to Present at the 31st Annual Piper Jaffray Healthcare Conference

October 24, 2019

CureVac to Present CV8102 Data at SITC Conference

August 13, 2019

CureVac Enters into an Exclusive Collaborative Research Agreement for Discovery Research in mRNA-based Lung Therapy Candidates with Yale University

July 12, 2019

CureVac to Participate in Two Panels at the ROTH RNA Revolution Conference

July 1, 2019

European Commission Appoints CureVac Co-Founder & Supervisory Board Chairman, Ingmar Hoerr, to the European Innovation Council Advisory Board

June 24, 2019

CureVac Welcomes Two Members to its Supervisory Board

June 13, 2019

CureVac Receives Grants for Three Patents Regarding Intratumoral Application of RNA

May 20, 2019

CureVac Enters into an Exclusive Sponsored Research Agreement for Discovery Research in mRNA-based Eye Therapy Candidates with the Schepens Eye Research Institute, Harvard Medical School and the Massachusetts Eye and Ear Infirmary

April 16, 2019

CureVac Granted Patent Claiming the Combination of mRNA Vaccines with Anti-PD-L1 Antibodies

April 9, 2019

CureVac to Participate in Upcoming Investor Conferences

March 21, 2019

CureVac Announces Late-Breaking Poster Presentation at American Association of Cancer Research (AACR) Annual Meeting 2019

February 27, 2019

CEPI awards US$ 34M contract to CureVac to advance The RNA Printer™—a disruptive, transportable mRNA vaccine manufacturing platform that can rapidly combat multiple diseases

February 19, 2019

CureVac to Present at the 8th Annual Leerink Partners Global Healthcare Conference

February 4, 2019

CureVac Appoints Stefan Mueller, Ph.D., as Vice President Preclinical

January 28, 2019

CureVac Appoints Dimitris Voliotis, M.D., Dr. med., as Chief Development Officer

January 8, 2019

CureVac Announces U.S. Patent Grant for mRNA Vaccination of Infants Against RSV

November 21, 2018

CureVac to Present at the 19th Annual Piper Jaffray Healthcare Conference

November 7, 2018

CureVac to Present Preliminary Phase I Data on CV8102, an Intratumoral RNA-based Cancer Therapy, at the 2018 Society for Immunotherapy of Cancer Annual Meeting

November 7, 2018

University of Tübingen Names CureVac Co-Founder & Supervisory Board Chairman, Ingmar Hoerr, Honorary Senator

October 23, 2018

CureVac Announces First Study Participant Enrolled in Phase I Clinical Trial Testing Prophylactic mRNA

June 12, 2018

CureVac Announces Appointment of Matthew L. S. Beck as Vice President of Investor Relations

May 8, 2018

CureVac Announces New Management Structure

March 22, 2018

CureVac Receives U.S. Patent Covering Entire Process for Pharmaceutical Manufacturing of RNA

February 18, 2018

CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria

January 18, 2018

CureVac Expands Intellectual Property Position that Significantly Improves Protein Expression for its mRNA-Based Vaccines and Therapeutics

January 10, 2018

CureVac Highlights Key 2018 Corporate Milestones and Outlook

January 4, 2018

CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics

December 28, 2017

CureVac to Present at the J.P. Morgan 35th Annual Healthcare Conference 2017

November 13, 2017

CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs

November 6, 2017

5th International mRNA Health Conference Highlights Rapid Clinical Progress and Cross-Industry Collaboration

October 29, 2017

CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics

October 27, 2017

CureVac Initiates Phase I Clinical Trial of RNAdjuvant® Candidate as Intratumoral Therapy for Solid Tumors

October 27, 2017

Publication in npj Vaccines Demonstrates CureVac’s RNActive® Vaccine is Superior to Licensed Vaccines

October 17, 2017

Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

August 15, 2017

Publication in EMBO Molecular Medicine Demonstrates CureVac’s Proprietary mRNA Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins and Tumors

July 31, 2017

5th International mRNA Health Conference to Showcase Tremendous Advances in the Development of mRNA Drugs

July 26, 2017

CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine

July 20, 2017

CureVac to Receive Patent Claiming the Combination of mRNA Vaccines with Anti-PD-1 Antibodies

June 26, 2017

CureVac Expands GMP Production Capacities for RNA Products

June 13, 2017

CureVac Extends Global Intellectual Property Estate for Prophylactic mRNA Vaccines

May 19, 2017

CureVac to Present at Upcoming International Investor Conferences

May 2, 2017

CureVac Appoints Daniel Menichella as CEO of CureVac Inc., the Company’s US Subsidiary

January 20, 2017

CureVac’s CEO, Ingmar Hoerr, Appointed by European Commission to High Level Group

January 11, 2017

CureVac Provides Clinical Update at 35th Annual J.P. Morgan Healthcare Conference

December 5, 2016

Study with CureVac’s RNAdjuvant® Technology Published in Cancer Immunology, Immunotherapy, Demonstrates Equal responsiveness of blood cells from Both Hepatocellular Carcinoma (HCC) Patients and Healthy Subjects to the RNA-based adjuvant

November 8, 2016

CureVac Secures an Additional $29.5 Million From Two New Investors

November 8, 2016

CureVac Receives Broad Patent for RNAntibody® Technology

October 11, 2016

CureVac Appoints Pierre Kemula as Chief Financial Officer

July 14, 2016

Study in Peer-Reviewed Journal Vaccine Demonstrates Decoding Mode of Action of mRNA Vaccines

March 30, 2016

CureVac Appoints Leading Experts to its Scientific Advisory Board

March 18, 2016

CureVac strengthens supervisory board to support global growth opportunities and mRNA product expansion

February 18, 2016

CureVac announces “MERAN” has been approved by the World Health Organization as suffix for mRNA drug substances

January 6, 2016

CureVac to Present at the 34th Annual J.P. Morgan Healthcare Conference

November 3, 2015

CureVac raises $110 Million in a private placement

September 10, 2015

IAVI and CureVac Partner to Accelerate Development and Testing of AIDS Vaccine Candidates

September 10, 2015

CureVac Establishes U.S. Operations in Cambridge, MA

September 3, 2015

CureVac to Present at BioCentury’s 22nd Annual NewsMakers in the Biotech Industry Conference

August 4, 2015

Collaboration to Develop mRNA Vaccines Expands

July 24, 2015

CureVac Announces Study Publication in Molecular Therapy Demonstrating Wide-Ranging Benefits of Sequence-Optimized, Unmodified mRNAs

July 7, 2015

CureVac Announces Phase I/IIa Clinical Study Data of its mRNA Cancer Immunotherapy in Prostate Cancer Published in the Journal for ImmunoTherapy of Cancer

March 5, 2015

The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology

September 18, 2014

Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy

December 16, 2013

CureVac Completes Patient Recruitment for Phase IIb Clinical Trial of mRNA-based Prostate Cancer Treatment

November 5, 2013

1st International mRNA Health Conference in Tübingen Heralds a New Era in Modern Medicine

November 4, 2013

CureVac Collaborates with the Cancer Research Institute and Ludwig Cancer Research to Enable Clinical Testing of Novel Immunotherapy Treatment Options for Cancer

October 3, 2013

CureVac to Collaborate with Janssen on Development of mRNA-Based Influenza Vaccine

April 10, 2013

CureVac’s CEO Ingmar Hoerr is Keynote Speaker at the Cancer Vaccines and Gene Therapy Meeting 2013 in Philadelphia

March 27, 2013

CureVac Initiates Phase 2b Clinical Trial of its mRNA-Based Cancer Vaccine in Patients with Castration-Resistant Prostate Cancer

November 25, 2012

Data Published in Nature Biotechnology Show Messenger (m)RNA Prophylactic Vaccines Based on CureVac’s RNActive® Technology Demonstrate Immunogenicity and Protection Against Influenza Virus Infection

September 18, 2012

CureVac Secures €80 Million in Series D Financing

November 7, 2011

CureVac presents clinical results of a Phase I/IIa trial in non-small cell lung cancer (NSCLC)

Media Contact

Corporate Communications

E-Mail

Dr. Sarah Fakih
Vice President Corporate Communications & Investor Relations
T +49 7071 9883 – 1298
M +49 160 – 90496949

E-Mail

April 8, 2025

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

April 7, 2025

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

March 27, 2025

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

February 18, 2025

CureVac Earns Repeat Recognition by LexisNexis® as One of the World’s Top Innovators

November 12, 2024

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

November 7, 2024

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

November 4, 2024

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

November 4, 2024

CureVac to Present at the 12th International mRNA Health Conference

October 28, 2024

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

September 13, 2024

CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

September 12, 2024

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

September 9, 2024

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

August 15, 2024

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

August 15, 2024

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

August 15, 2024

CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

July 11, 2024

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

July 3, 2024

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

July 3, 2024

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

June 24, 2024

[English only] CureVac Announces Voting Results of General Meeting

May 28, 2024

CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

May 23, 2024

CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update

April 24, 2024

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

April 24, 2024

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

April 24, 2024

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

April 18, 2024

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

April 16, 2024

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

April 4, 2024

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

January 17, 2024

[Form 6-K only / English only] CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock

January 5, 2024

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

December 19, 2023

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

November 14, 2023

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

November 1, 2023

CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

October 31, 2023

CureVac to Report Third Quarter and First Nine Months 2023 Financial Results and Business Updates on November 14, 2023

September 28, 2023

CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany

September 12, 2023

CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage

August 17, 2023

CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update

August 1, 2023

CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK

July 14, 2023

CureVac Announces Update to the Management Team

July 13, 2023

CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights

June 20, 2023

CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

June 20, 2023

CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board

June 19, 2023

[English only] CureVac Announces Voting Results of General Meeting

May 30, 2023

CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update

May 19, 2023

CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech

May 8, 2023

CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

April 25, 2023

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update

April 18, 2023

CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023

March 28, 2023

[English only] CureVac Announces Voting Results of Extraordinary General Meeting

February 10, 2023

CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares

February 8, 2023

CureVac Announces Pricing of Upsized Public Offering of Common Shares

January 9, 2023

CureVac Appoints Alexander Zehnder as CEO From April 1, 2023

February 6, 2023

CureVac Announces Proposed Public Offering of Common Shares

February 1, 2023

CureVac Welcomes Myriam Mendila as New Chief Development Officer

January 6, 2023

CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

January 31, 2023

CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis®

December 14, 2022

CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program

January 30, 2023

CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs

November 16, 2022

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update

November 11, 2022

CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

November 10, 2022

CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022

August 18, 2022

CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update

August 18, 2022

CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

July 5, 2022

CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech

June 22, 2022

CureVac Announces Voting Results of General Meeting

June 8, 2022

CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform

June 8, 2022

CureVac Announces Changes of CDO – Myriam Mendila to succeed Klaus Edvardsen

May 25, 2022

CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update

May 25, 2022

CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development

April 28, 2022

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update

April 22, 2022

CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022

April 21, 2022

CureVac and GSK’s Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study

April 11, 2022

CureVac and GSK Enter into Pandemic Preparedness Contract with German Government

March 30, 2022

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

March 1, 2022

CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer®

February 10, 2022

CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK

January 17, 2022

CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry

November 18, 2021

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update

November 18, 2021

CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine

November 10, 2021

CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response

October 12, 2021

CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology

September 14, 2021

CureVac Streamlines European Network for mRNA Product Manufacturing

August 31, 2021

CureVac’s CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet

August 30, 2021

CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

August 16, 2021

CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update

August 16, 2021

Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

June 30, 2021

CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60

June 30, 2021

CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer®

June 24, 2021

CureVac Announces Voting Results of General Meeting

June 23, 2021

CureVac Provides Supervisory Board Update

June 16, 2021

CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV

June 2, 2021

CureVac Appoints Klaus Edvardsen as Chief Development Officer

May 28, 2021

CureVac’s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation

May 26, 2021

CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates

May 13, 2021

Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study

April 19, 2021

CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic

April 15, 2021

CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020

April 9, 2021

CureVac to Report Fourth Quarter and Full-Year 2020 Financial Results and Business Updates on April 15, 2021

March 30, 2021

Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac’s COVID-19 Vaccine Candidate, CVnCoV

March 23, 2021

CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study

March 22, 2021

CureVac Expands CVnCoV COVID-19 Vaccine Candidate Clinical Trial Analyses to Include Phase 2b/3 Variant Specification and Efficacy Secondary Endpoint to Phase 2a

March 4, 2021

CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV

February 18, 2021

CureVac to Participate in Upcoming Investor Conferences

February 12, 2021

CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV

February 5, 2021

CureVac to Host Conference Call on COVID-19 Partnership Update on February 5, 2021

February 5, 2021

CureVac and UK Government to collaborate on development of vaccines against SARS-CoV-2 variants

February 4, 2021

CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma

February 4, 2021

CureVac Announces Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

February 3, 2021

GSK and CureVac to develop next generation mRNA COVID-19 vaccines – joint press release

February 2, 2021

CureVac Announces Closing of $450 million Follow-on Public Offering of Common Shares

February 1, 2021

CureVac and Rentschler Biopharma ramp up Manufacturing of COVID-19 Vaccine, CVnCoV – joint press release

January 28, 2021

CureVac Announces Pricing of $450 million Follow-on Public Offering of Common Shares

January 25, 2021

CureVac Announces Proposed Public Offering of Common Shares

January 11, 2021

CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection

January 7, 2021

CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV – joint press release

December 21, 2020

CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare Workers

December 14, 2020

CureVac Commences Global Pivotal Phase 2b/3 Trial for COVID-19 Vaccine Candidate, CVnCoV

December 9, 2020

CureVac and Fareva Sign Agreement For Fill & Finish Manufacturing of Curevac’s COVID-19 Vaccine Candidate, CVnCoV – joint press release

December 8, 2020

[German only] Moderne Wärme im Cyber Valley: Stadtwerke Tübingen versorgen neues Produktionsgebäude von CureVac – gemeinsame Pressemitteilung

December 4, 2020

CureVac Appoints Antony Blanc as Chief Business Officer and Chief Commercial Officer

November 30, 2020

CureVac Announces Financial Results and Business Updates for the Third Quarter and First Nine Months of 2020

November 26, 2020

CureVac to Report Third Quarter and First Nine Months 2020 Financial Results and Business Updates on November 30, 2020

November 23, 2020

CureVac and WACKER Sign Manufacturing Contract for CureVac’s COVID-19 Vaccine Candidate, CVnCoV – joint press release

November 17, 2020

CureVac Establishes European-Based Network to Ramp Up Manufacturing of its COVID-19 Vaccine Candidate, CVnCoV

November 16, 2020

European Commission Announces That Tomorrow It Will Authorize the Agreement with CureVac for the Supply of up to 405 Million Doses of mRNA-Based COVID-19 Vaccine Candidate, CVnCoV

November 12, 2020

CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Suitable for Standard Fridge Temperature Logistics

November 10, 2020

CureVac Publishes Detailed Interim Phase 1 Data of its COVID-19 Vaccine Candidate, CVnCoV

November 2, 2020

CureVac Reports Positive Interim Phase 1 Data for its COVID-19 Vaccine Candidate, CVnCoV

October 23, 2020

CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV

September 29, 2020

CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate

September 4, 2020

CureVac Expected to Receive up to 252 million Euros from the German Federal Ministry of Research for Further COVID-19 Vaccine Development and Production Capacity Expansion

August 20, 2020

CureVac and European Commission in Advanced Discussions to Supply up to 405 million doses of potential mRNA-based COVID-19 Vaccine

August 18, 2020

CureVac Announces Closing of Initial Public Offering

August 14, 2020

CureVac Announces Pricing of Initial Public Offering

August 10, 2020

CureVac Announces Proposed Initial Public Offering of Common Shares

August 4, 2020

CureVac Appoints Dr. Franz-Werner Haas as Chief Executive Officer and Dr. Igor Splawski as Chief Scientific Officer

July 21, 2020

CureVac Raises a Total of USD 640 Million in Private Financing Round

July 20, 2020

GSK and CureVac announce strategic mRNA technology collaboration

July 6, 2020

Germany: EIB and European Commission provide CureVac with a €75 million financing for vaccine development and expansion of manufacturing

July 1, 2020

Please note: Currently, there is no possibility to purchase shares of CureVac AG. Offers to purchase shares in CureVac AG are fraudulent.

June 17, 2020

CureVac Receives Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate

June 15, 2020

German Federal Government invests 300 Million Euros in CureVac

May 14, 2020

CureVac’s Optimized mRNA Platform Provides Positive Pre-Clinical Results at Low Dose for Coronavirus Vaccine Candidate

April 2, 2020

Jean Stéphenne Elected as New Chairman of the Supervisory Board of CureVac

March 17, 2020

COVID-19: Conference Call on Current Developments

March 16, 2020

CureVac announces leadership update

March 15, 2020

CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide

March 11, 2020

Company Founder Ingmar Hoerr Succeeds Daniel Menichella as CEO of CureVac AG

March 3, 2020

CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. President Donald Trump and Members of Coronavirus Task Force

February 26, 2020

CureVac Appoints Alan Kimura, MD, PhD as Head of the Newly Created Department “Rare Diseases”

January 31, 2020

CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019

January 7, 2020

CureVac Announces Positive Results in Low Dose – 1 µg – Rabies Vaccine Clinical Phase 1 Study

December 19, 2019

Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics

December 2, 2019

CureVac Granted Manufacturing Authorization for its Third GMP Production Suite

November 20, 2019

CureVac to Present at the 31st Annual Piper Jaffray Healthcare Conference

October 24, 2019

CureVac to Present CV8102 Data at SITC Conference

August 13, 2019

CureVac Enters into an Exclusive Collaborative Research Agreement for Discovery Research in mRNA-based Lung Therapy Candidates with Yale University

July 12, 2019

CureVac to Participate in Two Panels at the ROTH RNA Revolution Conference

July 1, 2019

European Commission Appoints CureVac Co-Founder & Supervisory Board Chairman, Ingmar Hoerr, to the European Innovation Council Advisory Board

June 24, 2019

CureVac Welcomes Two Members to its Supervisory Board

June 13, 2019

CureVac Receives Grants for Three Patents Regarding Intratumoral Application of RNA

May 20, 2019

CureVac Enters into an Exclusive Sponsored Research Agreement for Discovery Research in mRNA-based Eye Therapy Candidates with the Schepens Eye Research Institute, Harvard Medical School and the Massachusetts Eye and Ear Infirmary

April 16, 2019

CureVac Granted Patent Claiming the Combination of mRNA Vaccines with Anti-PD-L1 Antibodies

April 9, 2019

CureVac to Participate in Upcoming Investor Conferences

March 21, 2019

CureVac Announces Late-Breaking Poster Presentation at American Association of Cancer Research (AACR) Annual Meeting 2019

February 27, 2019

CEPI awards US$ 34M contract to CureVac to advance The RNA Printer™—a disruptive, transportable mRNA vaccine manufacturing platform that can rapidly combat multiple diseases

February 19, 2019

CureVac to Present at the 8th Annual Leerink Partners Global Healthcare Conference

February 4, 2019

CureVac Appoints Stefan Mueller, Ph.D., as Vice President Preclinical

January 28, 2019

CureVac Appoints Dimitris Voliotis, M.D., Dr. med., as Chief Development Officer

January 8, 2019

CureVac Announces U.S. Patent Grant for mRNA Vaccination of Infants Against RSV

November 21, 2018

CureVac to Present at the 19th Annual Piper Jaffray Healthcare Conference

November 7, 2018

CureVac to Present Preliminary Phase I Data on CV8102, an Intratumoral RNA-based Cancer Therapy, at the 2018 Society for Immunotherapy of Cancer Annual Meeting

November 7, 2018

University of Tübingen Names CureVac Co-Founder & Supervisory Board Chairman, Ingmar Hoerr, Honorary Senator

October 23, 2018

CureVac Announces First Study Participant Enrolled in Phase I Clinical Trial Testing Prophylactic mRNA

June 12, 2018

CureVac Announces Appointment of Matthew L. S. Beck as Vice President of Investor Relations

May 8, 2018

CureVac Announces New Management Structure

March 22, 2018

CureVac Receives U.S. Patent Covering Entire Process for Pharmaceutical Manufacturing of RNA

February 18, 2018

CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria

January 18, 2018

CureVac Expands Intellectual Property Position that Significantly Improves Protein Expression for its mRNA-Based Vaccines and Therapeutics

January 10, 2018

CureVac Highlights Key 2018 Corporate Milestones and Outlook

January 4, 2018

CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics

December 28, 2017

CureVac to Present at the J.P. Morgan 35th Annual Healthcare Conference 2017

November 13, 2017

CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs

November 6, 2017

5th International mRNA Health Conference Highlights Rapid Clinical Progress and Cross-Industry Collaboration

October 29, 2017

CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics

October 27, 2017

CureVac Initiates Phase I Clinical Trial of RNAdjuvant® Candidate as Intratumoral Therapy for Solid Tumors

October 27, 2017

Publication in npj Vaccines Demonstrates CureVac’s RNActive® Vaccine is Superior to Licensed Vaccines

October 17, 2017

Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

August 15, 2017

Publication in EMBO Molecular Medicine Demonstrates CureVac’s Proprietary mRNA Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins and Tumors

July 31, 2017

5th International mRNA Health Conference to Showcase Tremendous Advances in the Development of mRNA Drugs

July 26, 2017

CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine

July 20, 2017

CureVac to Receive Patent Claiming the Combination of mRNA Vaccines with Anti-PD-1 Antibodies

June 26, 2017

CureVac Expands GMP Production Capacities for RNA Products

June 13, 2017

CureVac Extends Global Intellectual Property Estate for Prophylactic mRNA Vaccines

May 19, 2017

CureVac to Present at Upcoming International Investor Conferences

May 2, 2017

CureVac Appoints Daniel Menichella as CEO of CureVac Inc., the Company’s US Subsidiary

January 20, 2017

CureVac’s CEO, Ingmar Hoerr, Appointed by European Commission to High Level Group

January 11, 2017

CureVac Provides Clinical Update at 35th Annual J.P. Morgan Healthcare Conference

December 5, 2016

Study with CureVac’s RNAdjuvant® Technology Published in Cancer Immunology, Immunotherapy, Demonstrates Equal responsiveness of blood cells from Both Hepatocellular Carcinoma (HCC) Patients and Healthy Subjects to the RNA-based adjuvant

November 8, 2016

CureVac Secures an Additional $29.5 Million From Two New Investors

November 8, 2016

CureVac Receives Broad Patent for RNAntibody® Technology

October 11, 2016

CureVac Appoints Pierre Kemula as Chief Financial Officer

July 14, 2016

Study in Peer-Reviewed Journal Vaccine Demonstrates Decoding Mode of Action of mRNA Vaccines

March 30, 2016

CureVac Appoints Leading Experts to its Scientific Advisory Board

March 18, 2016

CureVac strengthens supervisory board to support global growth opportunities and mRNA product expansion

February 18, 2016

CureVac announces “MERAN” has been approved by the World Health Organization as suffix for mRNA drug substances

January 6, 2016

CureVac to Present at the 34th Annual J.P. Morgan Healthcare Conference

November 3, 2015

CureVac raises $110 Million in a private placement

September 10, 2015

IAVI and CureVac Partner to Accelerate Development and Testing of AIDS Vaccine Candidates

September 10, 2015

CureVac Establishes U.S. Operations in Cambridge, MA

September 3, 2015

CureVac to Present at BioCentury’s 22nd Annual NewsMakers in the Biotech Industry Conference

August 4, 2015

Collaboration to Develop mRNA Vaccines Expands

July 24, 2015

CureVac Announces Study Publication in Molecular Therapy Demonstrating Wide-Ranging Benefits of Sequence-Optimized, Unmodified mRNAs

July 7, 2015

CureVac Announces Phase I/IIa Clinical Study Data of its mRNA Cancer Immunotherapy in Prostate Cancer Published in the Journal for ImmunoTherapy of Cancer

March 5, 2015

The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology

September 18, 2014

Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy

December 16, 2013

CureVac Completes Patient Recruitment for Phase IIb Clinical Trial of mRNA-based Prostate Cancer Treatment

November 5, 2013

1st International mRNA Health Conference in Tübingen Heralds a New Era in Modern Medicine

November 4, 2013

CureVac Collaborates with the Cancer Research Institute and Ludwig Cancer Research to Enable Clinical Testing of Novel Immunotherapy Treatment Options for Cancer

October 3, 2013

CureVac to Collaborate with Janssen on Development of mRNA-Based Influenza Vaccine

April 10, 2013

CureVac’s CEO Ingmar Hoerr is Keynote Speaker at the Cancer Vaccines and Gene Therapy Meeting 2013 in Philadelphia

March 27, 2013

CureVac Initiates Phase 2b Clinical Trial of its mRNA-Based Cancer Vaccine in Patients with Castration-Resistant Prostate Cancer

November 25, 2012

Data Published in Nature Biotechnology Show Messenger (m)RNA Prophylactic Vaccines Based on CureVac’s RNActive® Technology Demonstrate Immunogenicity and Protection Against Influenza Virus Infection

September 18, 2012

CureVac Secures €80 Million in Series D Financing

November 7, 2011

CureVac presents clinical results of a Phase I/IIa trial in non-small cell lung cancer (NSCLC)